Home / Market News / $MDCX

$MDCX news and market catalysts

The 10 most recent market catalysts affecting $MDCX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

10 catalysts 3 high impact 4 bullish 3 bearish Pharmaceuticals
Nov 13, 2026 Corporate Catalyst Bearish Impact 55
Brookline Capital Downgrades Medicus Pharma to Hold
Brookline Capital analyst Kumaraguru Raja downgraded Medicus Pharma (MDCX) to a 'Hold' rating. This action is significant as analyst ratings can influence investor sentiment and st…
Oct 26, 2026 Corporate Catalyst Bullish Impact 55
Medicus Pharma Ltd. Regains Compliance with Nasdaq Minimum Bid Price Requirement
Medicus Pharma Ltd. announced it has regained compliance with Nasdaq's $1.00 minimum bid price requirement, a significant hurdle for many small-cap companies. This development remo…
Oct 8, 2026 Corporate Catalyst Bearish Impact 85
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why
Medicus Pharma announced a 50-to-1 reverse stock split, a corporate action where the number of outstanding shares is reduced, and the price per share is proportionally increased. T…
Sep 29, 2026 Corporate Catalyst Neutral Impact 65
Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer
Medicus Pharma announced the submission of an optimized seamless Phase 2b/3 registration-intent protocol for Teverelix to the FDA. This is a crucial step in the drug development pr…
Sep 10, 2026 Corporate Catalyst Neutral Impact 65
Medicus Pharma Posts Phase 2 Clinical Study Report For SKNJCT‑003 On ClinicalTrials.gov, Offering Public Access To Efficacy, Safety, And Drug‑Delivery Findings
Medicus Pharma has made public the abridged Clinical Study Report for its SKNJCT-003 Phase 2 trial. This is a positive development as it increases transparency regarding the drug's…
Sep 8, 2026 Corporate Catalyst Bullish Impact 75
MDCX stock has given up its prior gain. Medicus Pharma shares were trading higher after the company provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company.
The headline highlights a classic 'buy the rumor, sell the news' scenario or a market re-evaluation of a corporate announcement. MDCX's strategic shift to precision oncology is a s…
Sep 3, 2026 Corporate Catalyst Bullish Impact 85
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma (MDCX) has entered a transformative licensing agreement with Pfizer (PFE) for an early-stage melanoma drug, PF-08046031 (CD228V). This is a major positive for Medicu…
Aug 12, 2026 Corporate Catalyst Bearish Impact 95
Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate
Medicus Pharma (MDCX) announced Q2 earnings per share of $(0.21), which missed the analyst consensus estimate of $(0.13) by a substantial 61.54%. This significant miss indicates th…
Jul 31, 2026 Corporate Catalyst Bullish Impact 65
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
Medicus Pharma secured regulatory clearance from the UAE Department of Health – Abu Dhabi for its PRECISION-E2 Phase 2a clinical study of Teverelix for moderate-to-severe symptomat…
Jul 27, 2026 Corporate Catalyst Neutral Impact 75
Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin Syndrome
Medicus Pharma announced that the FDA has issued a 'Study May Proceed' letter for its Investigational New Drug (IND) application for SKNJCT-005. This authorization allows Medicus t…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.